Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
NCT07619365Phase 2Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2026
- Primary completion
- Nov 2030
- Countries
- 1
01
Overview
Phase 2, open-label trial of lovastatin in breast cancer (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Objective Response Rate at 12 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
lovastatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07619365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619365.